Original Article
Postauthorization Safety Study (NISSO) Assessing the Long-Term Safety Profile of Sonidegib in Patients With Locally Advanced Basal Cell Carcinoma: Interim Analysis From the Spanish Cohort
S. Beà Ardébola,1, G.M. Pérez Pastorb,1, R. Fernández-de-Misac, R. Botella Estradad, V. Ruiz-Salase, Á. Flórezf, M. Mayor Arenalg, M.J. Fuente Gonzálezh, P. Bassas-Freixasi, A. Toll Abellój, P. Valerón Almazánk, R. Arntzl, J. Malvehy Guileraj,m,
Autor para correspondencia
a Hospital Universitario Ramón y Cajal, Dermatology Department, Madrid, Spain
b Consorcio Hospital General Universitario de Valencia, Dermatology Department, Valencia, Spain
c Hospital Universitario Nuestra Señora de Candelaria, Dermatology Department, Santa Cruz de Tenerife, Canary Islands, Spain
d Hospital Universitari i Politècnic La Fe, Dermatology Service, Valencia, Spain
e Hospital de la Santa Creu i Sant Pau, Dermatology Department, Barcelona, Spain
f Complexo Hospitalario Universitario de Pontevedra, Dermatology Department, Pontevedra, Spain
g Hospital Universitario La Paz, Dermatology Department, Madrid, Spain
h Hospital Germans Trials i Pujol, Dermatology Department, Badalona, Spain
i Hospital Universitari Vall d’Hebron, Dermatology Department, Barcelona, Spain
j Hospital Clínic de Barcelona, Dermatology Department, Barcelona, Spain
k Hospital Universitario de Gran Canaria Doctor Negrín, Dermatology Service, Las Palmas de Gran Canaria, Canary Islands, Spain
l Sun Pharmaceutical Industries B.V., Hoofddorp, The Netherlands
m IDIBAPS, CIBER deEnfermedades Raras, Instituto Carlos III, University of Barcelona, Barcelona, Spain
Ver más
